Publications by authors named "Pathou Nganzobo Ngima"
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial.
Victor Kande Betu Kumesu Wilfried Mutombo Kalonji Clélia Bardonneau Olaf Valverde Mordt Digas Ngolo Tete Pathou Nganzobo Ngima
Lancet Glob Health
November 2022
Background: Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults. We aimed to assess the safety and efficacy of fexinidazole in children across all disease stages of gambiense human African trypanosomiasis.
Methods: We did a multicentre, single-arm, open-label, phase 2-3 trial at eight district hospitals in the Democratic Republic of the Congo.
Article Synopsis
- Late-stage human African trypanosomiasis (g-HAT), caused by Trypanosoma brucei gambiense, has limited treatment options, typically requiring hospital-administered combination therapy, which is impractical for patients in remote areas.
- This study evaluated the safety and efficacy of an oral medication, fexinidazole, compared to the standard nifurtimox and eflornithine combination therapy in patients with late-stage g-HAT in the Democratic Republic of the Congo and Central African Republic.
- The trial was a randomized, open-label study with a primary endpoint measuring treatment success at 18 months, involving monitoring for both efficacy and safety of the medications administered.